Methylmalonic Acidemia (MMA)

Definition And Classification

Autosomal recessive organic acidemia caused by a defect in the conversion of L-methylmalonyl-CoA to succinyl-CoA.

Category	Subtypes And Characteristics
Isolated MMA	Mutase Deficiency: MMUT gene defects, classified into mut⁰ (complete deficiency) and mut⁻ (partial activity). Cobalamin Disorders: Defects in the synthesis of the adenosylcobalamin cofactor (cblA, cblB, cblD-MMA).
Combined MMA And Homocystinuria	Defects in cytosolic cobalamin metabolism, leading to combined methylmalonic acidemia and homocystinuria (cblC, cblD, cblF, cblJ, cblX).

The disease is caused by a deficiency of the enzyme Methylmalonyl-CoA Mutase (MCM) or its specific cofactor, 5-deoxyadenosylcobalamin.
Precursors of methylmalonyl-CoA include Isoleucine, Valine, Methionine, Threonine, odd-chain fatty acids, and cholesterol side chains.
The metabolic block results in the toxic accumulation of methylmalonic acid, propionyl-CoA, and methylcitrate.

Consequence	Mechanism
Mitochondrial Toxicity	Accumulation of metabolites inhibits the Krebs cycle (specifically citrate synthase) and impairs oxidative phosphorylation.
Hyperammonemia	Propionyl-CoA competitively inhibits N-acetylglutamate synthase (NAGS), causing secondary urea cycle dysfunction.
Hyperglycinemia	Toxic metabolites inhibit the glycine cleavage system.
Bone Marrow Suppression	Toxic effects lead to neutropenia and thrombocytopenia.

Neonatal Onset (Severe): Typically associated with mut⁰, presenting in the first week of life with a “sepsis-like” picture. Manifestations include poor feeding, vomiting, profound lethargy, and hypotonia. Patients show dehydration, hypothermia, Kussmaul breathing from severe acidosis, and rapid progression to seizures, coma, and death if untreated.
Chronic Or Intermittent (Late Onset): Associated with mut⁻ or cobalamin defects. Features include protein aversion, failure to thrive, chronic constipation, and developmental delay. Acute decompensation is typically triggered by catabolic stress such as infection, fasting, or high protein intake.

System	Specific Complications
Neurologic	Metabolic stroke affecting the globus pallidus in the basal ganglia, leading to movement disorders like dystonia, chorea, and spasticity.
Renal	Chronic tubulointerstitial nephritis leading to progressive Chronic Kidney Disease, a feature unique to Methylmalonic Acidemia compared to other organic acidemias.
Other Systems	Acute pancreatitis, optic nerve atrophy, cardiomyopathy, and acrodermatitis enteropathica-like skin rashes.

Test Category	Findings
Screening Labs	High anion gap metabolic acidosis, marked ketosis and ketonuria, mild to severe hyperammonemia, hyperglycinemia, and cytopenias (neutropenia, thrombocytopenia).
Urine Organic Acids	Massive elevation of Methylmalonic acid, alongside methylcitrate and 3-hydroxypropionate.
Plasma Acylcarnitine	Elevated C3 (propionylcarnitine) and C4DC (methylmalonylcarnitine).
Plasma Homocysteine	Essential to rule out combined Methylmalonic Acidemia and Homocystinuria (e.g., cblC disease).
Confirmatory Tests	Molecular genetics via gene panel testing for MMUT, MMAA, and MMAB. Clinical or in vitro Vitamin B12 responsiveness challenge.

Arrest Catabolism: Immediately halt exogenous protein intake for a maximum of 24-48 hours. Administer high-calorie intravenous fluids (10% Dextrose with intralipids) at 1.5 times maintenance to suppress endogenous protein breakdown.
Detoxification: Administer an intravenous loading dose of L-Carnitine (100 mg/kg) to facilitate the excretion of propionylcarnitine. Utilize ammonia scavengers such as Sodium Benzoate or Sodium Phenylacetate for hyperammonemia. Employ hemodialysis if severe acidosis or hyperammonemia is refractory to medical management.
Cofactor Therapy: Administer empirical intramuscular Hydroxocobalamin (Vitamin B12) at 1 mg/day.

Therapy Type	Interventions
Dietary	Low-protein diet restricting Isoleucine, Valine, Methionine, and Threonine, supplemented with specific medical foods. Avoidance of prolonged fasting.
Pharmacotherapy	Intramuscular Hydroxocobalamin for B12-responsive subtypes. Maintenance L-Carnitine (50-100 mg/kg/day). Gut sterilization using oral Metronidazole or Neomycin to decrease propionate production by enteric bacteria.
Transplantation	Liver transplantation corrects metabolic instability but fails to prevent chronic renal progression or reverse existing brain damage. Combined Liver-Kidney transplantation is indicated for patients exhibiting renal failure.

Prognosis heavily depends on the underlying subtype, with mut⁰ carrying the highest morbidity and poorest outcome.
Major long-term morbidities include irreversible intellectual disability, basal ganglia damage, and chronic renal failure.
While early diagnosis via Newborn Screening significantly improves initial survival, it does not completely prevent long-term systemic complications.